Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan;13(1):3-8.
doi: 10.1158/1541-7786.MCR-14-0343. Epub 2014 Oct 8.

Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift

Doug Medvetz  1 , Carmen Priolo  2 , Elizabeth P Henske  2
Affiliations
Review

Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift

Doug Medvetz et al. Mol Cancer Res. 2015 Jan.

Abstract

mTORC1 is an established master regulator of cellular metabolic homeostasis, via multiple mechanisms that include altered glucose and glutamine metabolism, and decreased autophagy. mTORC1 is hyperactive in the human disease tuberous sclerosis complex (TSC), an autosomal dominant disorder caused by germline mutations in the TSC1 or TSC2 gene. In TSC-deficient cells, metabolic wiring is extensively disrupted and rerouted as a consequence of mTORC1 hyperactivation, leading to multiple vulnerabilities, including "addiction" to glutamine, glucose, and autophagy. There is synergy between two rapidly evolving trajectories: elucidating the metabolic vulnerabilities of TSC-associated tumor cells, and the development of therapeutic agents that selectively target cancer-associated metabolic defects. The current review focuses on recent work supporting the targeting of cellular metabolic dysregulation for the treatment of tumors in TSC, with relevance to the many other human neoplasms with mTORC1 hyperactivation. These data expose a fundamental paradox in the therapeutic targeting of tumor cells with hyperactive mTORC1: inhibition of mTORC1 may not represent the optimal therapeutic strategy. Inhibiting mTORC1 "fixes" the metabolic vulnerabilities, results in a cytostatic response, and closes the door to metabolic targeting. In contrast, leaving mTORC1 active allows the metabolic vulnerabilities to be targeted with the potential for a cytocidal cellular response. The insights provided here suggest that therapeutic strategies for TSC and other tumors with activation of mTORC1 are at the verge of a major paradigm shift, in which optimal clinical responses will be accomplished by targeting mTORC1-associated metabolic vulnerabilities without inhibiting mTORC1 itself.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors disclose no potential conflicts of interest.

Figures

Figure 1
Figure 1
Selected inhibitors of glucose metabolism with potential efficacy in TSC. 3-BrPA – 3-bromopyruvic acid; 2-DG – 2-deoxyglucose; 6-AN – 6-aminonicotinamide.
Figure 2
Figure 2
Selected inhibitors of glutaminolysis with potential efficacy in TSC. DON - 6-Diazo-5-oxo-L-norleucine; EGCG - epigallocatechin-3-gallate.
Figure 3
Figure 3. Selected inhibitors of autophagy
Inhibitors highlighted in bold have shown potential efficacy in TSC. 3-MA – 3-methyladenine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412(2):179–90. - PMC - PubMed
    1. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans. 2009;37(Pt 1):217–22. - PMC - PubMed
    1. Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013;15(6):555–64. - PMC - PubMed
    1. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–56. - PubMed
    1. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93. - PMC - PubMed

MeSH terms

Substances